Our results indicate that the POLQ H-score obtained from immunohistochemistry is a valuable prognostic biomarker for pancreatic cancer outcomes, which may also contribute to the future design of more personalized therapies that improve patient prognoses. The gene discussed is POLQ; the disease is pancreatic neoplasm.